These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
307 related articles for article (PubMed ID: 36088504)
1. The roles of intratumour heterogeneity in the biology and treatment of pancreatic ductal adenocarcinoma. Evan T; Wang VM; Behrens A Oncogene; 2022 Oct; 41(42):4686-4695. PubMed ID: 36088504 [TBL] [Abstract][Full Text] [Related]
2. Single-cell profiling to explore pancreatic cancer heterogeneity, plasticity and response to therapy. Bärthel S; Falcomatà C; Rad R; Theis FJ; Saur D Nat Cancer; 2023 Apr; 4(4):454-467. PubMed ID: 36959420 [TBL] [Abstract][Full Text] [Related]
3. Hypoxia and pancreatic ductal adenocarcinoma. Yamasaki A; Yanai K; Onishi H Cancer Lett; 2020 Aug; 484():9-15. PubMed ID: 32380129 [TBL] [Abstract][Full Text] [Related]
4. Metastatic phenotype and immunosuppressive tumour microenvironment in pancreatic ductal adenocarcinoma: Key role of the urokinase plasminogen activator (PLAU). Hosen SMZ; Uddin MN; Xu Z; Buckley BJ; Perera C; Pang TCY; Mekapogu AR; Moni MA; Notta F; Gallinger S; Pirola R; Wilson J; Ranson M; Goldstein D; Apte M Front Immunol; 2022; 13():1060957. PubMed ID: 36591282 [TBL] [Abstract][Full Text] [Related]
5. Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions. Lin W; Noel P; Borazanci EH; Lee J; Amini A; Han IW; Heo JS; Jameson GS; Fraser C; Steinbach M; Woo Y; Fong Y; Cridebring D; Von Hoff DD; Park JO; Han H Genome Med; 2020 Sep; 12(1):80. PubMed ID: 32988401 [TBL] [Abstract][Full Text] [Related]
6. Tumor heterogeneity: An oncogenic driver of PDAC progression and therapy resistance under stress conditions. Palma AM; Vudatha V; Peixoto ML; Madan E Adv Cancer Res; 2023; 159():203-249. PubMed ID: 37268397 [TBL] [Abstract][Full Text] [Related]
7. Modeling pancreatic cancer in mice for experimental therapeutics. Mallya K; Gautam SK; Aithal A; Batra SK; Jain M Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188554. PubMed ID: 33945847 [TBL] [Abstract][Full Text] [Related]
8. The critical roles of activated stellate cells-mediated paracrine signaling, metabolism and onco-immunology in pancreatic ductal adenocarcinoma. Fu Y; Liu S; Zeng S; Shen H Mol Cancer; 2018 Feb; 17(1):62. PubMed ID: 29458370 [TBL] [Abstract][Full Text] [Related]
9. Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data. Connor AA; Gallinger S Nat Rev Cancer; 2022 Mar; 22(3):131-142. PubMed ID: 34789870 [TBL] [Abstract][Full Text] [Related]
10. Microenvironmental hCAP-18/LL-37 promotes pancreatic ductal adenocarcinoma by activating its cancer stem cell compartment. Sainz B; Alcala S; Garcia E; Sanchez-Ripoll Y; Azevedo MM; Cioffi M; Tatari M; Miranda-Lorenzo I; Hidalgo M; Gomez-Lopez G; Cañamero M; Erkan M; Kleeff J; García-Silva S; Sancho P; Hermann PC; Heeschen C Gut; 2015 Dec; 64(12):1921-35. PubMed ID: 25841238 [TBL] [Abstract][Full Text] [Related]
11. The Roles of Frequently Mutated Genes of Pancreatic Cancer in Regulation of Tumor Microenvironment. Sun H; Zhang B; Li H Technol Cancer Res Treat; 2020; 19():1533033820920969. PubMed ID: 32372692 [TBL] [Abstract][Full Text] [Related]
12. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications. Liu X; Xu J; Zhang B; Liu J; Liang C; Meng Q; Hua J; Yu X; Shi S Mol Cancer; 2019 Dec; 18(1):184. PubMed ID: 31831007 [TBL] [Abstract][Full Text] [Related]
13. Stromal biology and therapy in pancreatic cancer: ready for clinical translation? Neesse A; Bauer CA; Öhlund D; Lauth M; Buchholz M; Michl P; Tuveson DA; Gress TM Gut; 2019 Jan; 68(1):159-171. PubMed ID: 30177543 [TBL] [Abstract][Full Text] [Related]
14. Signaling Networks That Control Cellular Plasticity in Pancreatic Tumorigenesis, Progression, and Metastasis. Crawford HC; Pasca di Magliano M; Banerjee S Gastroenterology; 2019 May; 156(7):2073-2084. PubMed ID: 30716326 [TBL] [Abstract][Full Text] [Related]
15. Cell of origin affects tumour development and phenotype in pancreatic ductal adenocarcinoma. Lee AYL; Dubois CL; Sarai K; Zarei S; Schaeffer DF; Sander M; Kopp JL Gut; 2019 Mar; 68(3):487-498. PubMed ID: 29363536 [TBL] [Abstract][Full Text] [Related]
16. Pancreatic ductal adenocarcinoma: tumor microenvironment and problems in the development of novel therapeutic strategies. Kuznetsova A; Popova O; Panchenkov D; Dyuzheva T; Ivanov A Clin Exp Med; 2023 Jul; 23(3):619-643. PubMed ID: 36085429 [TBL] [Abstract][Full Text] [Related]
17. The tumor microenvironment in pancreatic ductal adenocarcinoma: current perspectives and future directions. Herting CJ; Karpovsky I; Lesinski GB Cancer Metastasis Rev; 2021 Sep; 40(3):675-689. PubMed ID: 34591240 [TBL] [Abstract][Full Text] [Related]
18. Crosstalk Between Peripheral Innervation and Pancreatic Ductal Adenocarcinoma. Ni B; Yin Y; Li Z; Wang J; Wang X; Wang K Neurosci Bull; 2023 Nov; 39(11):1717-1731. PubMed ID: 37347365 [TBL] [Abstract][Full Text] [Related]
19. Genetically engineered mouse models of pancreatic cancer: unravelling tumour biology and progressing translational oncology. Mazur PK; Siveke JT Gut; 2012 Oct; 61(10):1488-500. PubMed ID: 21873467 [TBL] [Abstract][Full Text] [Related]
20. Heterogeneity and plasticity of cancer-associated fibroblasts in the pancreatic tumor microenvironment. Boyd LNC; Andini KD; Peters GJ; Kazemier G; Giovannetti E Semin Cancer Biol; 2022 Jul; 82():184-196. PubMed ID: 33737108 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]